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Mini-Abstract:  We aimed to determine the effects of bisphosphonates on mechanical 26
properties independent of changes in bone density.  Our results show that at equivalent27
bone densities, vertebrae from beagles treated with bisphosphonate have equivalent bone 28
strength and reduced bone energy absorption compared to those from untreated animals.29
30
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Abstract31
32
Introduction:  Assessing the relationship between mechanical properties and bone 33
density allows a biomechanical evaluation of bone quality, with differences at a given 34
density indicative of altered quality.   The purpose of this study was to evaluate the 35
strength-density and energy absorption-density relationships in vertebral bone following 36
one-year treatment with clinical doses of two different bisphosphonates in beagle dogs.  37
Methods:  Areal bone mineral density (aBMD) and compressive mechanical properties 38
(ultimate load and energy absorption) were assessed on lumbar vertebrae from skeletally 39
mature beagle dogs treated with vehicle (VEH), alendronate (ALN), or risedronate (RIS).  40
Relationships among properties were assessed using analyses of covariance.41
Results:  Neither treatment altered the strength-density relationship compared to VEH, 42
suggesting increases in vertebral strength with bisphosphonate-treatment are explained by 43
increased density.  The energy absorption-density relationship was altered by ALN, 44
resulting in significantly lower energy absorption capacity at a given aBMD compared to 45
both VEH (-22%) and RIS (-14%).46
Conclusions:  These data document that after adjusting for increased aBMD, vertebrae 47
from animals treated with bisphosphonates have similar strength as those from untreated 48
animals.  Conversely, when adjusted for increased aBMD, alendronate treatment, but not 49
risedronate treatment, significantly reduces the energy required for vertebral fracture, 50
indicative of an alteration in bone quality.51
52
KEYWORDS:  Alendronate, Animal models, Mechanics, Risedronate53
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Introduction54
Bone mineral density (BMD) provides a convenient means of assessing fracture risk, but  55
it is well-accepted that skeletal factors other than BMD contribute to fracture prevention 56
(1, 2).  This is illustrated clinically by the disproportionate changes in BMD and fracture 57
risk reduction with anti-remodeling treatments, with variable changes in BMD associated 58
with similar reductions in fracture (3-5).  Such data have led to numerous studies 59
evaluating the effect of remodeling suppression on  factors other than bone density that 60
contribute to a bone’s fracture resistance (6).61
A bone's fracture resistance is determined by a combination of factors (7).  For 62
simplicity, these factors are oftentimes considered to include bone mass and “everything 63
else”.  Bone mass can be variably defined, yet clinically is routinely measured as areal 64
BMD (aBMD), a composite variable influenced by both bone mass (volume), bone size 65
and mineralization.  The “everything else”, often encompassed by the term bone quality, 66
includes factors such as whole bone geometry, microarchitecture, porosity, 67
mineralization, collagen organization and cross-linking, and microdamage accumulation.  68
Recently, Hernandez and Keaveny (6)  proposed that bone quality can be defined by 69
examining the relationship between measures of bone biomechanical performance and 70
bone density, with a change in the relationship indicative of a change in bone quality.71
Any change in bone strength or energy to fracture not accounted for by a change in bone 72
mass (aBMD) must be accounted for by other measures of bone as defined above (6).  If 73
a treatment has no effect on bone quality then the strength-density relationships would be 74
similar to untreated bone.  Conversely, if a treatment alters bone quality (either positively 75
or negatively) then the strength-density curve would differ relative to untreated bone.  76
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Although this approach does not address which component of bone quality is altered, it 77
does provide a useful starting point to determine if treatments alter biomechanical 78
properties through density-dependent or density-independent mechanisms.  We have 79
previously documented that the bisphosphonates risedronate and alendronate increase the 80
strength (~10%) and stiffness (~20%) of dog vertebrae following one-year treatment, but 81
reduce toughness non-significantly at doses used for the clinical treatment of osteoporosis 82
(8, 9), and significantly at doses used for the treatment of Paget’s disease (10).  The goal 83
of this study was to determine if these anti-remodeling agents alter vertebral bone quality 84
through assessment of the strength-density and energy absorption-density relationships.85
86
Methods87
Detailed methods regarding experimental design and tissue analyses have been 88
previously reported (8, 9).  Briefly, skeletally mature (range: 1-2 years old at initiation of 89
study; mean age 1.3 years) female beagle dogs (n=36; 12/group) were treated daily for 1 90
year with oral doses of saline vehicle (VEH), risedronate (RIS), or alendronate (ALN).  91
The doses of RIS (0.10 mg/kg/day) and ALN (0.20 mg/kg/day) represent the doses used 92
to treat post-menopausal osteoporosis on a mg/kg basis.  Following one year of treatment, 93
the fourth lumbar vertebra was excised and assessed for areal bone mineral density 94
(aBMD, PIXImus densitometer).  We chose to assess relationships using aBMD as this 95
technique is used clinically to evaluate vertebrae bone density.  Following endplate 96
removal, bones were tested in compression (10 mm/min) to determine mechanical 97
properties.  Ultimate load was defined as the maximal load achieved during the test, 98
while energy absorption was defined as the area under the load/displacement curve up to 99
Page 4 of 14
http://mc.manuscriptcentral.com/oi
Osteoporosis International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Page 5 of 13
the point of ultimate load.  The strength-density and energy absorption-density 100
relationships were compared among groups using analyses of covariance.  When groups 101
had similar slopes, least square means (LSM) were compared to determine differences in 102
parameters after accounting for aBMD.   For all tests, p < 0.05 was considered 103
significant. 104
105
Results106
As previously described, vertebral aBMD was significantly increased with ALN (0.36 + 107
0.02 g/cm2), but not RIS (0.33 + 0.02 g/cm2), compared to VEH (0.33 + 0.02 g/cm2) (8).  108
There was no significant difference in the strength-density relationship between VEH (y 109
= 17264x - 1927.2) and either RIS or ALN nor between the two bisphosphonates together 110
(pooled y = 16709x - 1724.8) (Figure 1A). 111
 There was no significant difference among groups in the slope of the energy 112
absorption-density relationship, yet the intercepts differed significantly (Figure 1B).  113
After adjusting for aBMD, the energy absorption capacity was significantly lower in 114
ALN-treated specimens compared to both VEH (LSM = -22%, p = 0.02) and RIS (LSM 115
= -14%, p = 0.02).  There was no significant difference between VEH and RIS (p=0.12) 116
for energy absorption after accounting for differences in aBMD.  117
118
Discussion119
Anti-remodeling agents are clearly beneficial for reducing fracture risk in post-120
menopausal osteoporotic women, as well as various other populations.  Despite this clear 121
efficacy, the mechanism of fracture risk reduction with these agents is poorly understood 122
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beyond the suppression of osteoclast activity.  The current study shows that any change 123
in vertebral bone strength with bisphosphonate-treatment can be explained entirely by 124
increased density.  Additionally, these data show that alendronate-treated bone, but not 125
risedronate-treated bone, required significantly less energy to fracture than untreated 126
controls at a given bone density. 127
The current study shows bisphosphonates enhance compressive vertebral bone 128
strength by increasing bone density: the regression line depicting the strength-density 129
relationship is not significantly different for either RIS or ALN treatments compared to 130
VEH.  As we have previously noted, the increases in vertebral compressive strength with 131
ALN and RIS were 10% and 9.5%, respectively, both non-significant (8).  We have also 132
previously reported no difference in the ultimate load to aBMD ratio between vehicle-133
and bisphosphonate-treated specimens (9).  Assessing the relationship between 134
biomechanical properties using the current method (regression analyses) as opposed to 135
using the ratio of strength/density of each specimen provides different information, yet 136
the two are not mutually exclusive (6).  If the relationships are linear, with non-zero 137
intercepts (as they are here, see Figure 1), or if the relationships are non-linear, the ratios 138
can differ even when the data follow the same relationship.  It is therefore important to 139
use both approaches (ratios and strength-density plots) to comprehensively assess 140
changes in bone quality.  141
In addition to bone strength, the energy absorption capacity of a bone is important 142
to determine fracture resistance (11).  After accounting for increased density with 143
alendronate-treatment, the energy absorption capacity is significantly impaired compared 144
to specimens from animals treated with VEH (-22%) and RIS (-14%).  This is contrasted 145
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to risedronate-treatment, which did not significantly alter the energy absorption-density 146
relationship compared to vehicle.  The reduced energy absorption capacity per unit 147
aBMD in ALN-treated animals is consistent with previous results showing a trend toward 148
reduced bone toughness, the tissue’s ability to absorb energy, at doses used for the 149
treatment of osteoporosis (9) and significant reductions in toughness at doses used for the 150
treatment of Paget’s disease (10).  This suggests an additional increment in vertebral 151
BMD is necessary with alendronate treatment to maintain energy absorption capacity at a 152
level comparable to non-treated bone.  153
These data emphasize the importance of examining changes in numerous 154
biomechanical properties, as the relationships between strength and density, and between 155
energy to failure with density, were different for a given treatment.  In addition, it 156
remains unclear whether bone strength, energy absorption, or some other biomechanical 157
parameter is most directly related to clinical fracture risk of the spine.  Bone strength and 158
energy absorption are believed to be governed by different parameters.  The mineral 159
component plays a significant role in determining the pre-yield properties of bone --160
strength and stiffness (12, 13), whereas the organic component dominates the post-yield 161
deformation that accounts for energy absorption (14).  Therefore, treatment-induced 162
changes in mineral- or collagen-related bone quality parameters may only manifest in 163
those biomechanical properties in which each is predominant. Numerous studies (15-17)164
have shown that bisphosphonates increase average tissue mineralization as well as 165
mineralization homogeneity.  This is consistent with our data that show increased 166
strength associated with increased aBMD following bisphosphonate treatment.  We have 167
shown alterations to collagen maturity and cross-linking of vertebral bone in dogs 168
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following 1 year treatment with bisphosphonates (18).  The non-enzymatic glycation of 169
bone caused by bisphosphonate treatment has been shown to reduce post-yield 170
deformation of bone (19).  Increased formation of non-enzymatically-mediated cross 171
links (such as pentosidine) is consistent with the aBMD-normalized reduction in energy 172
to fracture demonstrated here.  Changes in microarchitecture could also play a role, as 173
even with similar bone volumes, subtle changes in the trabecular architecture could alter 174
various mechanical properties including energy absorption (20, 21).175
In clinical trials, alendronate has been shown to produce greater remodeling 176
suppression than risedronate (22).  Analyses of turnover suppression in the canine 177
vertebrae in this study showed similar suppression at potency-equivalent doses of ALN 178
and RIS relative to VEH-treated animals (-66 and 74%, respectively) (8).  Differences in 179
turnover rates, or rather the degree of turnover suppression, would produce differences in 180
microarchitecture as well as properties of the material that are dictated by remodeling rate 181
(e.g. mineralization, collagen cross-linking, and microdamage).  Whether these non-182
significant differences in turnover suppression between ALN and RIS in this study 183
account for the different results with respect to the aBMD- nergy absorption relationship 184
is unclear.185
These data should be considered in the context of various limitations. The use of 186
intact, non-ovariectomized beagle dogs may limit the translation of these results to post-187
menopausal women.  In addition, we have also only assessed one site (vertebra) and 188
therefore cannot definitively state whether these changes in bone quality are applicable to 189
other clinically-relevant bone sites.  Finally, as the goal of this study was to determine to 190
relative contribution of aBMD and ‘everything else’ to the whole bone mechanical 191
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properties, these data do not specifically address the mechanism by which alendronate 192
reduces bone quality with respect to energy absorption.  To address such issues, specific 193
material-level mechanical tests such as those using samples with defined geometry or 194
micro-mechanical tests including nanoindentation, are necessary.     195
In conclusion, these data document bisphosphonates exert a positive effect on 196
vertebral bone strength through increases in density.  The data also show that 197
alendronate, but not risedronate, significantly reduces vertebral energy required to 198
fracture, when normalized by bone density.  Given the known role of the organic matrix 199
in determining energy absorption capacity, some effort should be made to determine the 200
effects of bisphosphonate treatment on the amount, maturity and cross-linking of the 201
collagen moiety in bone matrix and its role in altering mechanical properties. 202
203
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Figure Legend.217
Figure 1.  Strength-density (A) and energy absorption-density (B) relationships of 218
vertebral bone from beagles treated for 1 year with vehicle or clinical doses of 219
risedronate, or alendronate.  The strength-density relationship was similar for untreated 220
(vehicle (), y = 17264x - 1927.2) and bisphosphonate-treated animals (pooled (),y = 221
16709x - 1724.8).  BP-treated groups were combined as there was no difference between 222
RIS (y = 24551x - 4132) and ALN (y = 10051x + 464) for the strength-density 223
relationship.  The energy absorption-density relationship differed from untreated (, y = 224
9717x - 1437) and risedronate-treated (, y = 12559x – 2604) animals compared to 225
those treated with alendronate (, y = 8542x – 1439).  226
227
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